PI-RADS v2 Score Independently Predicts Bone Metastasis in Newly Diagnosed Prostate Cancer

PI-RADS v2 score ≥5, alongside tPSA, cTx, and ALP, independently predicted bone metastasis in prostate cancer (n=325). Nomogram sensitivity 81.3%, specificity 74.5%; external validation: 78.4%/79.1%. Retrospective, two-center study.

• Retrospective two-center study of 325 newly diagnosed prostate cancer patients; multivariate analysis identified PI-RADS v2 score, tPSA, bone turnover marker cTx, and ALP as independent predictors of bone metastasis.
• Nomogram achieved sensitivity 81.3% and specificity 74.5% internally (leave-one-out cross-validation accuracy 79.8%); external validation in a separate cohort yielded sensitivity 78.4% and specificity 79.1% (AUC and 95% CIs not reported in source).
• Key limitation: retrospective design with modest sample size (n=325 across two centers) limits generalizability; prospective multicenter validation needed before clinical adoption.

RadPigeon summaries are original and for information only. They are not clinical advice.